DNA vaccines against chronic lung infections by Pseudomonas aeruginosa

FEMS Immunology and Medical Microbiology

Volumn 37, Issue 2-3, 2003, Pages 147-153

  Staczek, J ^a   Gilleland, L B ^a   Van Der Heyde, H C ^a   Gilleland Jr , H E ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Antibody mediated immunity; Cell mediated immunity; DNA vaccine; Pseudomonas aeruginosa; Pulmonary chronic infection

Indexed keywords

ANTIBODY; CD3 ANTIGEN; CYTOKINE; DNA VACCINE; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN F; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT ENHANCEMENT; ARTICLE; B LYMPHOCYTE; BIOLISTIC TRANSFORMATION; CELL POPULATION; CELLULAR IMMUNITY; CHRONIC LUNG DISEASE; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; EXPRESSION VECTOR; GENE GUN; GENE TARGETING; IMMUNIZATION; IMMUNOCOMPETENT CELL; LUNG INFECTION; MOUSE; NONHUMAN; OUTBREEDING; PRIORITY JOURNAL; PROVOCATION TEST; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM;

EID: 0038433309     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(03)00075-0     Document Type: Article

References (38)

1. Holder I.A., Volpel K., Ronald G., Paranchych W. Studies on multiple Pseudomonas aeruginosa isolates from individual burn patients by RFLP, O antigen serotyping and antibiogram analysis. Burns. 21:1995;441-444.
2. Nagesha C.N., Shenoy K.J., Chandrashekar M.R. Study of burn sepsis with special reference to Pseudomonas aeruginosa. J. Indian Med. Assoc. 94:1996;230-233.
3. Chevalier X., Lavabre C., Claudepierre P., Larget-Piet B. Iatrogenically induced vertebral osteomyelitis due to Pseudomonas aeruginosa. Clin. Exp. Rheumatol. 14:1996;191-194.
4. Fergie J.E., Shema S.J., Lott L., Crawford R., Patrick C.C. Pseudomonas aeruginosa bacteremia in immunocompromised children: analysis of factors associated with a poor outcome. Clin. Infect. Dis. 18:1994;390-394.
5. Gonzalez-Barca E., Fernandez-Sevilla A., Carratala J., Granena A., Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur. J. Clin. Microbiol. Infect. Dis. 15:1996;291-296.
6. Krcmery V. Jr., Trupl J., Kunova A., Spanik S., Ilavska I., Hel'pianska L., Bezakova I., Drgona L., Oravcova E., Studena M., Lacka J., Sevcikova L., Koren P., Kukuckova E., Stopkova K., Krupova I., Grausova S., Svec J. Imipenem-resistant Ps. aeruginosa bacteraemia in cancer patients: risk factors, clinical features and outcome. Bratisl. Lek. List. 97:1996;647-651.
7. Raje N.S., Rao S.R., Iyer R.S., Kelkar R.S., Pai S.K., Nair C.N., Kurkure P.A., Magrath I.T., Advani S.H. Infection analysis in acute lymphoblastic leukemia: a report of 499 consecutive episodes in India. Pediatr. Hematol. Oncol. 11:1994;271-280.
8. Cassiere, H.A. and Fein, A.M. (1997) Severe community-acquired pneumonia. Medscape Respir. Care 1.
9. Ely E.W. Pneumonia in the elderly: Diagnostic and therapeutic challenges. Infect. Med. 14:1997;643-654.
10. High K.P. Pneumonia in the elderly: New approach to an old problem. Infect. Med. 14:1997;617-618.
11. Hoïby N., Koch C. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax. 45:1990;881-884.
12. Zach M.S. Pathogenesis and management of lung disease in cystic fibrosis. J. R. Soc. Med. 84:(Suppl. 18):1991;10-17.
13. Hancock R.E. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin. Infect. Dis. 27:(Suppl. 1):1998;S93-9.
14. Ma D., Cook D.N., Hearst J.E., Nikaido H. Efflux pumps and drug resistance in gram-negative bacteria. Trends Microbiol. 2:1994;489-493.
15. Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science. 264:1994;382-388.
16. Nikaido H. Multidrug efflux pumps of gram-negative bacteria. J. Bacteriol. 178:1996;5853-5859.
17. Gilleland H.E. Jr., Gilleland L.B., Matthews-Greer J.M. Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model. Infect. Immun. 56:1988;1017-1022.
18. Gilleland H.E. Jr., Gilleland L.B., Hughes E.E., Matthews-Greer J.M. Recombinant outer membrane protein F of Pseudomonas aeruginosa elicits antibodies that mediate opsonophagocytic killing, but not complement-mediated bacteriolysis, of various strains of P. aeruginosa. Curr. Microbiol. 24:1992;1-7.
19. Gilleland H.E. Jr., Hughes E.E., Gilleland L.B., Matthews-Greer J.M., Staczek J. Use of synthetic peptides to identify surface-exposed, B cell epitopes within outer membrane protein F of Pseudomonas aeruginosa. Curr. Microbiol. 31:1995;279-286.
20. Staczek J., Gilleland H.E. Jr., Gilleland L.B., Harty R.N., Garcia-Sastre A., Engelhardt O.G., Palese P. A chimeric influenza virus expressing an epitope of outer membrane protein F of Pseudomonas aeruginosa affords protection against challenge with P. aeruginosa in a murine model of chronic pulmonary infection. Infect. Immun. 66:1998;3990-3994.
21. Staczek J., Bendahmane M., Gilleland L.B., Beachy R.N., Gilleland H.E. Jr. Immunization with a chimeric tobacco mosaic virus containing an epitope of outer membrane protein F of Pseudomonas aeruginosa provides protection against challenge with P. aeruginosa. Vaccine. 18:2000;2266-2274.
22. Price B., Galloway D.R., Baker N.R., Gilleland L.B., Staczek J., Gilleland H.E. Jr. Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunizations against the outer membrane protein F (OprF) of P. aeruginosa. Infect. Immun. 69:2001;3510-3515.
23. Price B., Galloway D.R., vonSpecht B.-U., Gilleland L.B., Gilleland H.E. Jr., Staczek J. Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa. FEMS Immunol. Med. Microbiol. 23:2002;33-43.
24. Knapp B., Hundt E., Lenz U., Hungerer K.-D., Gabelsberger J., Domdey H., Mansour E., Li Y., vonSpecht B.-U. A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa. Vaccine. 17:1999;11663-11666.
25. Hughes E.E., Gilleland L.B., Gilleland H.E. Jr. Synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa that elicit antibodies reactive with whole cells of heterologous immunotype strains of P. aeruginosa. Infect. Immun. 60:1992;3497-3503.
26. Matthews-Greer J.M., Gilleland H.E. Jr. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model. J. Infect. Dis. 155:1987;01282-1291.
27. Bruderer U., Furer E., Cryz S.J. Jr., Lang A.B. Properties determining the potential of naturally occurring and vaccine-induced human antibodies to protect against lethal infection of Pseudomonas aeruginosa. Res. Immunol. 143:1992;165-174.
28. Tosi M.F., Zakem-Cloud H., Demko C.A., Schreiber J.R., Stern R.C., Konstan M.W., Berger M. Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. J. Infect. Dis. 172:1995;453-461.
29. Pier G.B., Small G.J., Warren H.B. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections. Science. 249:1990;537-549.
30. Ciofu O., Petersen T.D., Jensen P., Hoïby N. Avidity of anti-P. aeruginosa antibodies during chronic infection in patients with cystic fibrosis. Thorax. 54:1999;141-144.
31. Gilleland H.E. Jr., Gilleland L.B., Fowler M.R. Vaccine efficacies of elastase, exotoxin A, and outer membrane protein F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model. J. Med. Microbiol. 38:1993;79-86.
32. Gilleland H.E. Jr., Parker M.G., Matthews J.M., Berg R.D. Use of purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice. Infect. Immun. 44:1984;49-54.
33. Pier G.B. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients. Behring Inst. Mitt. 98:1997;350-360.
34. Cripps A.W., Dunkley M.L., Clancy R.L., Kyd J. Vaccine strategies against Pseudomonas aeruginosa infection in the lung. Behring Inst. Mitt. 98:1997;262-268.
35. Johansen H.K., Cryz S.J. Jr., Hougen H.P., Moser C., Hoïby N. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia. A new prophylactic principle. Behring Inst. Mitt. 98:1997;269-273.
36. Lei D., Lancaster J.R. Jr., Joshi M.S., Nelson S., Stoltz D., Bagby G.J., Odom G., Shellito J.E., Kolls J.K. Activation of alveolar macrophages and lung host defenses using transfer of the interferon-gamma gene. Am. J. Physiol. 272:1997;L852-L859.
37. Song Z., Johansen H.K., Faber V., Moser C., Kharazmi A., Rygaard J., Hoïby N. Ginseng treatment reduces bacterial load and lung pathology in chronic Pseudomonas aeruginosa pneumonia in rats. Antimicrob. Agents Chemother. 41:1997;961-964.
38. Song Z., Kharazmi A., Wu H., Faber V., Moser C., Krogh H.K., Rygaard J., Hoïby N. Effects of ginseng treatment on neutrophil chemiluminescence and immunoglobulin G subclasses in a rat model of chronic Pseudomonas aeruginosa pneumonia. Clin. Diagn. Lab. Immunol. 5:1998;882-887.